Companies › Neela Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Sep 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CLN-301 Intrathecal AAV9 gene therapy for CLN3 replacement | CLN3 | Phase 1 | CLN3 | Sep 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03770572 | CLN-301 | Phase 1 | CLN3 | Metabolic and endocrine | Sep 2029 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.